MAR 0 3 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Day Application of: Matthew Peterson et al.

Serial No.:

10/820,382

Group No.:

1625

Filed:

04/08/2004

Examiner:

Not Yet Assigned

For:

GABAPENTIN COMPOSITIONS

Attorney Docket Number:

TPIP039

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Applicants submit these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(d)(2). The Commissioner is hereby authorized to charge this fee of \$180.00 to Deposit Account No. 502626.

CERTIFICATE OF MAILING BY EXPRESS MAIL
CERTIFICATE OF MAILING BY EXPRESS MAIL I hereby certify that under 37 CFR §1.10 that this correspondence is being deposited on
the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage in an envelope addressed to:
Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA22313-1450.
Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Kristin Miele

I hereby certify that no item of information contained in this supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making a reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The Applicant respectfully requests that:

a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and

b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Respectfully submitted,

Reg. No. 28,469

M. Andrea Ryan, Senior Patent Counsel

, 2006

Transform Pharmaceuticals, Inc.

29 Hartwell Avenue

Lexington, MA 02421

Telephone: (781) 674-7852 Facsimile: (781) 863-7208

•

2

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO		Complete if Known		
	Oubstrate for form 1440/110		Application Number	10/820,382	
SIP	EINFORMATION D	ISCLOSURE	Filing Date	4/8/2004	
_	STATEMENT BY APPLICANT		First Named Inventor	Matthew Peterson	
0	ج الله عدد many sheets الم	as necessari	Art Unit	1625	
			Examiner Name	Celia C. Chang	
ENZ FE	OBJ 1	of 1	Attorney Docket Number	TPIP039	

Initials* No.1 the item (book, magazine, journal, serial, symposium, catalog		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Stahl et al., "Handbook of Pharmaceutical Salts Properties, Selection and Use", Pblished jointly by VHCA and Wiley, 2002	
		Variankaval et al., "Preparation and Solid-State Characterization of Nonstoichiometric Cocrystals of a" Crystal Growth and Design, Pgs. A-K (publ. on Web 1/21/2006)	

Examiner	 Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.